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Background
Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, progressive, debilitating and life-threatening neurodegenerative disease. TTR-FAP is a rare disease worldwide. In Europe a disease is defined as rare when it affects less than 1 in 2000 inhabitants. Portugal has the largest cluster worldwide nonetheless recent Portuguese epidemiologic data is lacking. The purpose of this study is to estimate TTR-FAP prevalence in Portugal.
Methods
In Portugal, TTR-FAP patient's medicines utilization is fully funded by National Health Service since 2001. Since March 2013 Portuguese electronic prescription system became more generalized, allowing central monitoring and validation of medicines prescription and dispensing. TTR-FAP anonymized patient's prescription data was requested to Administração Central do Sistema Saúde (ACSS). For each prescription the database has information regarding the local where the medicines were dispensed. Hence, for each patient, the most frequent municipality was identified and used as a proxy for residence. Portuguese total population by municipality was obtained from the official source -Instituto Nacional de Estatística. Prevalence was reported for mainland country and by municipality as number of cases per 2000 inhabitants.
Results
Trough year 2014, a total of 70286 electronic dispensing acts were detected in ACSS database, unravelling a total of 2013 distinctive TTR-FAP patients in Portugal. 
Conclusion
We can estimate that TTR-FAP disease has a current prevalence of 0,41 per 2000 inhabitants in Portugal and it is now disseminated across the country being Póvoa de Varzim historically and still the most impacted municipality with 3,95 cases per 2000 inhabitants, nearly ten times higher than overall country prevalence. 
